Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uptravi in pulmonary arterial hypertension (GRIPHON extension)
NCT01112306Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2010
- Primary completion
- Aug 2021
- Countries
- 38
01
Overview
A Phase 3 trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2010; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01112306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01112306.